Aim: Identification of risk factors predicting the development of death rattle.
antimuscarinics reduce secretion production, but do not remove secretions that have already pooled in the airways (Back, Jenkins, Blower, & Beckhelling, 2001; Bennett et al., 2002) . In addition, effectiveness of pharmacological treatments have been shown to be variable, making standardization of treatment impossible which renders decision-making difficult for both prescribers and nurses who commonly administer these drugs (Ahmedzai, 2015; Hirsch, Marriott, & Faull, 2012) . It is unknown whether death rattle causes distress in patients, but distress levels can be high in family members (Shimizu et al., 2013) . The identification of risk factors associated with the development of death rattle would allow for prophylactic treatments or at least enable early interventions (K ass & Ellershaw, 2003; Sheehan, Clark, Lam, & Chye, 2011; Wildiers et al., 2009 ). This article reports on a retrospective case ̶ control study that investigated potential risk factors associated with the development of death rattle in a dying adult.
| Background
Risk factors associated with the development of death rattle have been investigated by several research groups, either as their main objective or in supplementary examinations of cohort characteristics (Bennett, 1996; Campbell & Yarandi, 2013; Clark, Currow, Agar, Fazekas, & Abernethy, 2008; Ellershaw, Sutcliffe, & Saunders, 1995;  Jakobsson, Gaston-Johansson, Ohl en, & Bergh, 2008; K ass & Ellershaw, 2003; Morita, Tsunoda, Inoue, & Chihara, 2000; Morita et al., 2004 Morita et al., , 2005 Nakajima, Hata, & Kusumuto, 2013; Pace et al., 2009; Sheehan et al., 2011; Wildiers & Menten, 2002; Yamaguchi et al., 2012) . Many potential risk factors were identified in these studies, but there was no consensus regarding risk factors which may predict the development of death rattle in a dying adult. Table 1 illustrates the findings from these different researchers in chronological order which set the context for this current study.
A systematic review was conducted to establish risk factors studied in relation to death rattle (Kolb, Snowden, & Stevens, 2018) . This paper describes the empirical investigation of the risk factors discovered in that review alongside other potential risk factors not previously examined. The rationale for their inclusion is explained next.
| Weight
Anorexia is a common problem in dying cancer patients and can often result in considerable weight loss and cachexia (Mondello et al., 2015; Morita et al., 2004) . Alternatively, cancer modifying treatment, medication for symptom management and peripheral oedema can lead to substantial weight gain (Jakobsson et al., 2008;  Schmitz, DiSipio, Gordon, & Hayes, 2014; Sturdza et al., 2008) . It is known that obesity can cause pulmonary complications and worsen respiratory diseases (Koenig, 2001; Zammit, Liddicoat, Moonsie, & Makker, 2010) . Therefore, weight was included as an original variable to be tested for association with death rattle.
| Smoking history
Smoking is known to affect the respiratory system (Arcavi & Benowitz, 2004) and lung pathology was suggested to be a risk factor of death rattle (K ass & Ellershaw, 2003) . K ass and Ellershaw (2003) recommended inclusion of a patient's smoking history into future studies. They had found a significantly higher risk of death rattle in men and suggested that smoking might explain at least part of the association. Hence, smoking history was included as an original variable.
| Medications
First line drug treatment for death rattle are antimuscarinic medications, such as hyoscine hydrobromide, hyoscine butylbromide or Why is this research or review needed?
• In a systematic review and narrative analysis conducted by the authors no clear and undisputed risk factors were identified that predicted the development of death rattle in dying adults.
• The identification of one or more risk factors predictive of death rattle development could lead to more targeted treatments and perhaps prophylaxis.
What are the key findings?
• Weight, smoking habits, final opioid doses and final midazolam doses were investigated as potential risk factors for death rattle for the first time. Weight, smoking habits and final opioid doses were not found to be associated with the development of death rattle.
• Midazolam given at the end of life increased the likelihood of death rattle, especially in dying adults who required increasing doses of midazolam.
How should the findings be used to influence policy/practice/research/education?
• Clinicians should be mindful that dying adults with a higher dose requirement for midazolam have an increased likelihood of developing death rattle.
• Midazolam is commonly used in end-of-life care worldwide and future research should investigate the relationship between the development of death rattle and the administration of midazolam. glycopyrronium bromide, a subgroup of anticholinergic medications.
They antagonize acetylcholine and thereby block parasympathetic activity leading to decreased production of airway secretions (Prommer, 2013 ). Other medications, especially medications given to elder people and in palliative care, have anticholinergic properties causing side effects like dry mouth (Hoyle, Bostock, & MacLeod, 2012 Metastases Investigated by : Ellershaw et al. (1995) , Bennett (1996) , Morita et al. (2000 Morita et al. ( , 2004 , Wildiers and Menten (2002) , Sheehan et al. (2011), Campbell and Yarandi (2013) Diagnosis Investigated by : Ellershaw et al. (1995) , Bennett (1996) , Morita et al. (2000 Morita et al. ( , 2004 , Wildiers and Menten (2002) , Sheehan et al. (2011 ), Campbell and Yarandi (2013 . If medications given at the end of life contribute to the anticholinergic burden, then either they could provide protection from death rattle or, as Sheehan et al. (2011) found, might increase its risk. Although opioids and benzodiazepines in the form of Midazolam are only mildly anticholinergic, these are the medications most frequently given to patients at the end of life (Lindqvist et al., 2013) .
Therefore, doses of these two medication groups on day of death were included as original potential risk factors.
The aim of the study was to identify risk factors that are associated with the development of death rattle in a dying adult.
| Design
Retrospective case-control study where 200 medical records were reviewed. 
| Participants

| Data collection
Data pertaining to the following potential risk factors associated with the development of death rattle were extracted from medical records and tabulated (see also (Bennett, 1996; Ellershaw et al., 1995; K ass & Ellershaw, 2003; Morita et al., 2000 Morita et al., , 2004 . Using the opioid conversion chart for equianalgesia from Oxford Desk Reference/ Oncology all opioid doses were converted to subcutaneous morphine sulphate so that a consistent scale variable could be created (Laird & Fallon, 2011) . The anticholinergic load scores of medications prescribed five days before death were determined using the anticholinergic drug scale (ADS) as presented by Lertxundi, Domingo-Echaburu, Hernandez, Peral, and Medrano (2012) and total scores calculated.
Drug dosages were grouped into categories given that association with death rattle will have been likely to be non-linear. Choice of cut-off points was largely arbitrary, aimed at both providing reasonable numbers in each group for analysis while also giving indication of low (or no), medium and high drug dosages.
| Ethical considerations
Research Ethics Committee approval was granted for this research pro- 
| Data analysis
First, a pre-selection process was carried out: univariate analyses were applied to all 15 variables using Pearson's chi-square (Table 5) T A B L E 3 Descriptive statistics of scale variables 
| Validity, reliability and rigour
A series of procedures were used to test the regression model regarding goodness-of-fit (Field, 2013) . Besides the Hosmer and
Lemeshaw goodness-of-fit test, Field (2013) and Pallant (2007) advise the examination of residuals to test how well the model fits regarding two aspects: first, which cases exert an undue influence on the model and second, for which cases the model does not fit.
These residual tests were run with the logistic regression in SPSS.
Finally, multi-collinearity diagnostics were performed. All test results confirmed a good model fit and absence of multi-collinearity.
| RESULTS
The age range of the studied patients was 41-93 years with a mean of 72 years (SD 11.56). Sex was equally distributed with 47% male (N = 94) and 53% female patients (N = 106).
Only 4.5% (N = 9) had a non-malignant diagnosis. In this sample, 75.5% developed death rattle while 24.5% did not. The results of the descriptive analyses of the data are included in Tables 3 and 4. Midazolam was associated with death rattle at higher dosages.
The apparent association between the final opioid dose and death rattle was confounded by the administration of midazolam. With both drugs included in a single model, only midazolam remained significant. Estimates suggested that the association between higher dosages of midazolam and death rattle were high, with an odds ratio indicating those receiving the higher dosage to be more than three times as likely to experience a death rattle. However, despite the statistically significant results confidence intervals were wide given the relatively small numbers of people in the study and so estimates need to be treated with caution.
| Length of dying phase
It has been suggested that a prolonged dying process might be associated with the development of death rattle (K ass & Ellershaw, 2003) .
Duration of the dying process was assessed by researchers in different ways, either as LOS defined as survival time from admission to death or as duration of the terminal phase in hours. In this study LOS and terminal phase were both assessed. There was no association between LOS and death rattle found. The terminal phase was measured in days on an end-of-life pathway. Patients for whom this specific documentation was not used presumably died unexpectedly and fast. In these cases, length of dying phase was coded as zero days. Although length of dying phase was associated with death rattle according to the result of the Mann-Whitney U test (p = 0.013), it had no contributing value to the regression model and was excluded from it.
Two studies had previously investigated associations between LOS and death rattle and their findings contradicted each other (Bennett, 1996; Morita et al., 2000) . K ass and Ellershaw (2003) Nagelkerke r 2 = 0.11. studies found that anticholinergic properties of medication were not protective of death rattle for the patients.
| Final opioid dose
In the univariate analysis, final opioid dose was associated with death rattle. However, it was not statistically significant in the regression analysis. The variable was retained, however, as single predictor models do not take interactions between variables into account (Field, 2013) . Masman, van Dijk, Tibboel, Baar, and Mathôt (2015) showed that the median dose had increased to 60 mg/24 hrs since their previous assessment.
It is possible that midazolam did not cause death rattle in these cases. Despite the dose dependent relationship, the statistical model used cannot attribute causality and therefore further research will be needed. Also, the final model only explained 11%
variance. Nevertheless, it is plausible to consider midazolam as a contributing factor. It is believed that death rattle is caused by the inability to clear secretion from the airways due to a reduced swallow and cough reflex (Bennett, 1996) . It is reasonable to speculate that midazolam would make this situation worse. Midazolam is a muscle relaxant and given in the terminal phase might result in the relaxation of the throat thereby further decreasing the ability to clear secretion that gathered (Back et al., 2001 ).
| Limitations
The retrospective nature of the study affected the quality of the data, particularly the measurement of weight, consciousness levels, smoking history and infection status. It also led to the exclusion of hydration levels at the outset as this was not recorded in the medical records.
Furthermore, doses of midazolam and opioids were obtained from regular prescriptions. There is a possibility that results might have been different if "as required" medication had been included. However, it was common practice in the study setting to include "as required" medication from the previous 24 hr in the prescription of the continuous subcutaneous infusion for the next 24 hr. This meant that the data on midazolam doses reflected precisely the previous 24 hr. As the day of death was of various lengths for individual patients the inclusion of prn medication from that time would have blurred the picture rather than increased the precision.
Data was cross-sectional. It is very possible that those with a death rattle were more likely to receive midazolam. It may be that healthcare professionals were more likely to perceive a person to be in distress if they had a death rattle. If so, then the association will reflect that concern, rather than the drug causing the rattle. That explanation is notable given implications for drug use in palliative care. Further research is clearly needed.
It could be argued that data from a prospective approach might have been of higher quality. However, as this study investigated a symptom that only occurs in the last days and hours of life, the cohort could be easily identified in a retrospective approach, including all patients who died in the studied time frame irrespective of their diagnosis or characteristics. This study could easily be replicated (Earle & Ayanian, 2006) .
The model only explained a little over 11% of the variance.
Given that only two independent variables were included in the model, that is, in itself a reasonably good fit. The other 89% of variance will likely have included factors relating to both the patient and those providing care.
Finally, data collection was carried out in a hospice where most patients had a diagnosis of cancer and where very proactive symptom management was implemented. The generalizability to nonmalignant diagnoses and other settings is not known.
| CONCLUSION
This study investigated potential risk factors associated with the development of death rattle in adults at the end of life. It included analysis of risk factors that had not been investigated before. For the first time, medications given regularly in the terminal phase were investigated and the midazolam dose given on the last day of life was identified as a risk factor for the development of death rattle.
This discovery is potentially important for practice and should be investigated further.
| Recommendations for practice
Midazolam is a common medication used in the last hours of life to treat a range of symptoms such as agitation, delirium or breathlessness (HIS, 2014) . Scottish Palliative Care Guidelines (HIS, 2014) state that midazolam should be titrated in 5-10 mg steps. This study has shown that midazolam dose was associated with the development of death rattle at higher doses. Medical and nursing professionals are advised to closely monitor patients who fall into this risk group, especially when doses of midazolam increase as the patient approaches death. This study has shown the odds ratio associated with developing a death rattle was only statistically significant with doses over 20 mg where there was a nearly fourfold increase in the likelihood. This is a clinically relevant finding given 60 mg was the median dose of midazolam in Masman et al.'s study (2015) .
It is recommended that pharmacological treatment of death rattle is started as soon as possible to enable this to be reduced (Back et al., 2001; Bennett et al., 2002) . Prophylactic treatment for death rattle is not recommended in the British national palliative care guidelines (Ahmedzai, 2015) , but has been discussed in the literature (Bradley, Wee, & Aoun, 2010; Hugel, Ellershaw, & Gambles, 2006; K ass & Ellershaw, 2003) . Future research could investigate the feasibility of prophylactically treating patients who fall into a risk group or investigate alternative pharmacological management to replace midazolam for some indication.
5.2 | Recommendations for future research
| Risk factors
As highlighted in the limitations, some imprecision in the data became apparent during data collection. While these variables (i.e.
weight, consciousness levels, smoking history and infection status)
were non-significant in this study, the affected variables could be risk factors for death rattle if investigated in a future project with more accurate data.
| Prophylactic treatment
Following the identification of a risk group new treatment options for death rattle should be considered. The feasibility of prophylactic treatment could be gauged in future research.
| Midazolam
Logistic regression is unable to determine a causal relationship between an increased likelihood of developing death rattle with an increase in the midazolam dose. Future research should use a different study design to explore why midazolam is administered to individual patients and whether there is a causal connection between the development of death rattle and this medication at differing doses. 
